Immune cell contributions to sarcopenia: Evidence from genetic analyses Authors: Yuanjie Duan, Juan Liu, Shiyu Lin, Xi Li, Dan Luo, Lemei Zhu Published: 2026 ABSTRACT Recent evidence suggests a potential role of immune cell activity in the development of sarcopenia, but the causal relationship remains unclear. To address this, we conducted a bidirectional 2-sample Mendelian randomization (MR) analysis to evaluate whether immune cell traits causally influence sarcopenia. Genetic instruments for 731 immune cell traits were derived from a cohort of 3757 individuals of European ancestry, and sarcopenia-related data (including hand grip strength, appendicular lean mass, and walking pace—) were obtained from large-scale genome-wide association studies of European populations. Causal effects were estimated using inverse-variance weighted and weighted median MR, with MR-Egger regression applied for sensitivity analyses. Our results identified several immune cell traits with significant causal effects on sarcopenia. Increased expression of human leukocyte antigen-DR on plasmacytoid and total conventional dendritic cells, as well as human leukocyte antigen-DR on cluster of differentiation 33− myeloid cells, was associated with lower appendicular lean mass, slower walking pace, and higher risk of low hand grip strength. Conversely, certain lymphoid cell traits, including higher numbers of specific T and B cell subsets, were associated with protective effects against sarcopenia. Reverse MR analyses indicated no strong causal effects of sarcopenia traits on immune cell profiles. These findings provide robust genetic evidence supporting a causal link between immune cell composition and sarcopenia, highlighting myeloid cells as potential contributors to sarcopenia development, while lymphoid cells may exert protective effects. This insight advances our understanding of sarcopenia pathophysiology and may inform future preventive and therapeutic strategies. 1. Introduction Sarcopenia, classified as a geriatric syndrome, is defined by the Asian Working Group for Sarcopenia as an “age-related loss of skeletal muscle mass plus loss of muscle strength and/or reduced physical performance.”[1–3] This progressive and widespread skeletal muscle disorder entails the accelerated decline in both muscle mass and function, leading to heightened risks of adverse outcomes such as falls, functional decline, frailty, and mortality.[4,5] The impact of sarcopenia on disease burden arises due to its relatively common occurrence, with reported prevalence rates ranging from 12.9 to 40.4%, and its association with both short-term and long-term adverse effects.[5,6] However, the pathogenesis of sarcopenia is not yet well understood, which hinders the advancement of diagnosis and treatment. In the pathogenesis of sarcopenia, immune cells have consistently been an important topic. The interaction between immune cells and skeletal muscles plays a crucial role in the regenerative capacity of skeletal muscles.[7–9] Under normal circumstances, immune cells infiltrate into the skeletal muscle tissue, identifying and clearing necrotic and apoptotic cells, and secreting essential growth factors that promote proliferation and differentiation.[10,11] However, with the aging of the body, the immune system also undergoes an aging process, called immune aging, manifested by the degeneration of immune structures and abnormal functions. Inflammation significantly alters the environment of skeletal muscles, leading to a reduction in muscle mass and causing other complications.[12] Unique low-level inflammation has been observed in immune aging, resulting from an increase in pro-inflammatory factors and a decrease in anti-inflammatory factors due to immune abnormalities.[13–16] In a persistent inflammatory environment, multimeric protein complex promotes the processing and activation of pro-inflammatory forms of interleukin interleukin-1β and interleukin-18, triggering the activation of cysteine proteases and causing a vicious cycle of pro-inflammatory conditions leading to a decrease in muscle mass.[17–20] Many studies have reported abnormalities in the types and quantities of immune cells in sarcopenia patients compared to normal individuals.[21,22] However, there is a lack of exploration into the roles of immune cells in promoting inflammation and providing anti-inflammatory effects in sarcopenia, as well as further discussions on the causal relationship between various immune cells and sarcopenia. Based on existing findings, our study, for the first time, conducted a 2-sample bidirectional Mendelian randomization (MR) analysis using genome-wide association study (GWAS) data on immune cells and sarcopenia to explore the causal relationship between them. The discoveries from our research can provide evidence and direction for the study of the relationship between the immune system and sarcopenia, offering new insights for the early prevention, diagnosis, and treatment of sarcopenia in clinical settings. 2. Methods 2.1. Study design To investigate the potential causal relationship between immune cells and sarcopenia, we conducted a bidirectional 2-sample MR analysis. Unlike previous studies that only considered grip strength, we expanded the sarcopenia phenotypes to include 3 core indicators: hand grip strength, appendicular lean mass (ALM), and walking pace, thereby providing a more comprehensive representation of the key components of sarcopenia. 2.2. GWAS data sources Genetic variation data for immune cells were obtained from a cohort of 3757 individuals of European ancestry. This cohort included 7 immune cell panels: B cells; conventional dendritic cells (cDC); T cell maturation stages; monocytes; myeloid cells; T cells, B cells, and natural killer cells; and Treg cells, covering a total of 731 immune cell traits. Sarcopenia-related data were sourced as follows: hand grip strength (ebi-a-GCST90007526) from a GWAS meta-analysis of 256,523 individuals aged ≥ 60 years of European ancestry; ALM (ebi-a-GCST90000025) from 450,243 European individuals; and walking pace (ukb-b-4711) from 459,915 European individuals. 2.3. Selection of instrumental variables (IVs) To ensure the validity of MR analyses, selected IVs were required to meet 3 criteria: relevance, with single nucleotide polymorphisms (SNPs) strongly associated with the exposure (F-statistic ≥ 10); exclusivity, with SNPs affecting the outcome only through the exposure and no horizontal pleiotropy; and independence, with SNPs not associated with potential confounders. In forward MR, immune cell traits were treated as exposures with a lenient threshold of P < 1 × 10−5. In reverse MR, the 3 sarcopenia phenotypes were treated as exposures, and immune cell traits as outcomes, using a stringent threshold of P < 5 × 10−8. Linkage disequilibrium was set at R2 = 0.001 within a 10,000 kb window, and minor allele frequency ≥ 0.05. 2.4. Statistical analyses In forward MR, each immune cell trait was analyzed against hand grip strength, ALM, and walking pace separately. The intersection of significant results across the 3 phenotypes was considered to identify immune cell traits with clear causal effects. Reverse MR followed the same approach, treating each sarcopenia phenotype as the exposure and immune cell traits as outcomes; the intersecting immune cell traits were considered to be causally influenced by sarcopenia. All analyses were performed using R version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria). Causal estimates were primarily derived using inverse-variance weighted (IVW) and weighted median methods, with results presented as β coefficients with 95% confidence intervals (CIs). For binary outcomes (e.g., low hand grip strength), β represents log-odds, with a positive β indicating that the exposure may increase the likelihood of the outcome and a negative β indicating that the exposure may decrease the likelihood of the outcome. For continuous outcomes (e.g., ALM or walking pace), β represents the average change in the outcome per unit increase in the exposure, with a positive β indicating an increase in the outcome value (e.g., higher ALM, potentially more favorable) and a negative β indicating a decrease (e.g., lower ALM or walking pace, potentially less favorable). Statistical significance was determined using IVW or weighted median methods, with P < .05 indicating evidence of a causal effect. For traits with multiple SNPs, MR-Egger regression was additionally applied for sensitivity analysis. Heterogeneity was assessed using Cochran Q test, with P < .05 indicating significant heterogeneity. Horizontal pleiotropy was evaluated via the MR-Egger intercept, and the leave-one-out method was employed to assess the robustness of results. 3. Results In the forward 2-sample MR analysis, we assessed the potential causal effects of immune cell traits on sarcopenia-related phenotypes, including hand grip strength, ALM, and walking pace. The Venn diagram (Fig. 1) illustrates the overlap of immune cell traits significantly associated with each phenotype. Specifically, 46 traits were associated only with low hand grip strength, 64 with ALM, and 51 with walking pace, while 3 traits were consistently associated across all 3 phenotypes (Fig. 2). Causal effects of immune cell traits on sarcopenia-related phenotypes. CD33 = cluster of differentiation 33, cDC = conventional dendritic cells, CI = confidence interval, DC = dendritic cells, HLA = human leukocyte antigen, IVW = inverse-variance weighted, MR = Mendelian randomization. Venn diagram of immune cell traits associated with sarcopenia-related phenotypes. Causal estimates derived from the IVW and weighted median methods are presented as β coefficients with 95% CI. Significant effects were indicated when P values from either IVW or weighted median were < .05. Key findings include: cDC: human leukocyte antigen (HLA)-DR expression on plasmacytoid DCs was negatively associated with ALM (IVW β = −0.005, 95% CI: −0.012 to 0.003; weighted median β = −0.017, 95% CI: −0.023 to −0.011) and walking pace (IVW β = −0.002, 95% CI: −0.004 to 0.001; weighted median β = −0.004, 95% CI: −0.006 to −0.001). Conversely, positive associations were observed with low hand grip strength (IVW β = 0.036, 95% CI: 0.011 to 0.061; weighted median β = 0.045, 95% CI: 0.013 to 0.078). cDC (HLA-DR on total dendritic cells): Similar patterns were observed, with negative effects on ALM (IVW β = −0.005, 95% CI: −0.014 to 0.004; weighted median β = −0.015, 95% CI: −0.022 to −0.008) and walking pace (IVW β = −0.002, 95% CI: −0.005 to 0.000; weighted median β = −0.005, 95% CI: −0.008 to −0.003) and a positive association with low hand grip strength (IVW β = 0.043, 95% CI: 0.011 to 0.075). Myeloid cells: HLA-DR expression on cluster of differentiation 33− HLA-DR+ myeloid cells exhibited negative associations with ALM (IVW β = −0.010, 95% CI: −0.019 to −0.001) and walking pace (weighted median β = −0.005, 95% CI: −0.009 to −0.001), whereas positive effects were noted for low hand grip strength (IVW β = 0.043, 95% CI: 0.001 to 0.078) (Fig. 3). Causal effects of immune cell traits on sarcopenia-related phenotypes estimated by 2-sample Mendelian randomization. cDC = conventional dendritic cells, CI = confidence interval, IVW = inverse-variance weighted, MR = Mendelian randomization, nSNP = number of single nucleotide polymorphism. Overall, these results suggest that specific immune cell traits may differentially influence components of sarcopenia, with several cDC and myeloid cell traits consistently associated with reduced muscle mass, slower walking pace, and decreased grip strength. The MR-Egger intercept test did not detect significant horizontal pleiotropy, indicating no evidence of bias from pleiotropic effects. Sensitivity analyses using the leave-one-out method confirmed that the causal estimates were robust to the exclusion of individual IVs. Furthermore, Cochran Q test statistics indicated no significant heterogeneity across the included IVs (Table S1). In the reverse 2-sample MR analysis, sarcopenia-related traits (low hand grip strength, ALM, and walking pace) were treated as exposures to examine their potential causal effects on 731 immune cell traits. The Venn diagram (Fig. 2) shows that no immune cell traits were significantly associated with all 3 sarcopenia phenotypes simultaneously. Specifically, 14 traits were associated only with hand grip strength, 28 with ALM, and 13 with walking pace, while no traits overlapped across phenotypes (Fig. 4). Venn diagram of immune cell traits potentially influenced by sarcopenia-related phenotypes. These findings suggest an absence of strong reverse causal effects of sarcopenia traits on immune cell profiles. In other words, the data do not support the hypothesis that sarcopenia drives changes in the immune cell traits evaluated in this study. 4. Discussion In this bidirectional MR study, we investigated the causal relationships between immune cell traits and sarcopenia-related phenotypes, including hand grip strength, ALM, and walking pace. Our findings indicate that several conventional dendritic cell (cDC) and myeloid cell traits are likely causal contributors to sarcopenia components. Specifically, HLA-DR expression on plasmacytoid DCs and total cDCs, as well as HLA-DR on cluster of differentiation 33− myeloid cells, were associated with decreased ALM and slower walking pace, while simultaneously increasing the risk of low hand grip strength. These results suggest a differential influence of immune cell subsets on muscle mass, strength, and function, highlighting a potential immunometabolic component in sarcopenia pathogenesis. Mechanistically, cDCs are pivotal regulators of T cell responses and cytokine secretion, which may influence skeletal muscle protein turnover and regeneration.[23–25] Dysregulated cDC activity could promote a pro-inflammatory environment, exacerbating muscle catabolism and impairing muscle stem cell function. Myeloid cells, particularly HLA-DR+ subsets, may similarly affect systemic inflammation, tissue repair, and local microvascular function, which are critical for muscle maintenance.[26–29] These findings align with previous observational studies linking chronic low-grade inflammation and immune activation to sarcopenia, but extend them by providing evidence of directionality and causal inference using genetic instruments. Moreover, the convergence of multiple immune cell traits on all 3 sarcopenia phenotypes suggests that immune dysregulation may broadly affect both muscle mass and functional performance. The reverse MR analysis did not reveal significant causal effects of sarcopenia traits on immune cell profiles, supporting the notion that muscle loss and functional decline are unlikely to induce systemic changes in the evaluated immune cell subsets. This observation strengthens the argument that immune dysregulation may precede and contribute to sarcopenia rather than being a consequence of muscle decline. From a clinical perspective, these findings highlight potential immunomodulatory targets for sarcopenia prevention and intervention. Therapies that modulate cDC or myeloid cell activity, attenuate chronic inflammation, or restore immune homeostasis may help preserve muscle mass and function in aging populations.[30–33] Additionally, our results suggest that immune profiling could serve as a biomarker for early identification of individuals at higher risk of sarcopenia, facilitating timely interventions such as tailored exercise, nutritional supplementation, or pharmacological strategies.[32,34,35] Several limitations should be acknowledged. First, all GWAS data were derived from European populations, limiting generalizability to other ethnicities. Second, while we applied sensitivity analyses to control for horizontal pleiotropy and confounding, residual bias cannot be entirely excluded. Third, the immune cell phenotypes were measured in peripheral blood, which may not fully capture tissue-resident immune cell dynamics in muscle. Fourth, while MR provides evidence for causality, effect sizes are modest, indicating that immune cell traits are only part of a multifactorial etiology that includes physical activity, nutrition, comorbidities, and genetic background. Future studies should validate these findings in diverse populations and incorporate longitudinal immune profiling alongside muscle imaging and functional assessments. Experimental studies exploring the molecular pathways linking cDC and myeloid cell activity to muscle protein turnover and regeneration will be essential for translating these findings into therapeutic strategies. Integration of metabolomic and transcriptomic data may further elucidate the immune-muscle crosstalk underlying sarcopenia. 5. Conclusion In conclusion, this study provides genetic evidence supporting a causal role for specific dendritic and myeloid cell traits in sarcopenia, emphasizing the potential of immune-targeted interventions to prevent or ameliorate age-related muscle loss and functional decline. These findings contribute to a deeper understanding of sarcopenia pathophysiology and highlight novel avenues for research and clinical application. Acknowledgments We are very grateful to the providers of the GWAS data. Author contributions Conceptualization: Yuanjie Duan, Juan Liu, Shiyu Lin, Lemei Zhu. Data curation: Yuanjie Duan, Juan Liu, Shiyu Lin, Xi Li, Lemei Zhu. Investigation: Lemei Zhu. Methodology: Yuanjie Duan, Juan Liu, Shiyu Lin, Dan Luo, Lemei Zhu. Resources: Yuanjie Duan, Juan Liu, Dan Luo. Software: Yuanjie Duan, Juan Liu, Shiyu Lin, Xi Li, Dan Luo, Lemei Zhu. Supervision: Lemei Zhu. Visualization: Xi Li. Writing – original draft: Yuanjie Duan, Juan Liu, Lemei Zhu. Writing – review & editing: Yuanjie Duan, Juan Liu, Lemei Zhu.